Welcome to our dedicated page for Monte Rosa Therapeutics news (Ticker: GLUE), a resource for investors and traders seeking the latest updates and insights on Monte Rosa Therapeutics stock.
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines. The GLUE news page on Stock Titan highlights company announcements that reflect progress across its oncology, immunology, and inflammation programs, as well as its capital markets and collaboration activities.
Investors following Monte Rosa news will see updates on its key clinical candidates, including MRT-2359, a GSPT1-directed MGD being evaluated in MYC-driven solid tumors such as metastatic castration-resistant prostate cancer, and MRT-8102, a NEK7-directed MGD in Phase 1 development for inflammatory diseases driven by the NLRP3 inflammasome, IL-1β, and IL-6. News items also cover MRT-6160, a VAV1-directed MGD for immune-mediated diseases being advanced with Novartis, and preclinical programs targeting cyclin E1 and CDK2.
Typical GLUE news coverage includes clinical trial updates (interim Phase 1 and Phase 1/2 data, study expansions, and planned Phase 2 trials), scientific presentations at major conferences, and collaboration milestones with partners such as Novartis and Roche. Financial and corporate releases, including quarterly results, cash runway commentary, and details of public offerings of common stock and pre-funded warrants, provide additional context on the company’s funding strategy.
By reviewing Monte Rosa’s news feed, readers can track how the company’s QuEEN™ discovery engine is translated into clinical programs, follow the evolution of its MGD pipeline in oncology and immune-mediated diseases, and monitor material events disclosed through press releases that are often cross-referenced in SEC filings. Bookmark this page to access a consolidated view of GLUE-related announcements as they are released.
Monte Rosa Therapeutics (Nasdaq: GLUE) reported Q4 and full‑year 2025 results and program updates on March 17, 2026. Key clinical highlights include MRT-8102 showing an 85% CRP reduction after four weeks and 94% of participants reaching CRP <2 mg/L. The company closed a $345M follow‑on financing and reports cash and marketable securities of $382.1M as of Dec 31, 2025, supporting operations into 2029.
Other items: favorable safety/tolerability data for MRT-8102; MRT-2359 showed 100% PSA responses in a 5/5 AR‑mutant mCRPC subset; planned Phase 2 starts in 2026–2027; Novartis and Roche collaborations provide milestone upside.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced a supply agreement with Johnson & Johnson to support a planned Phase 2 study of MRT-2359 plus apalutamide for metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor (AR) mutations.
The signal-confirming Phase 2 is expected to start in Q3 2026, will enroll up to 25 patients, and will assess PSA response, RECIST response, duration of response, PFS, rPFS, and safety. Prior positive Phase 1/2 combination data were presented on Feb 26, 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) reported updated Phase 1/2 data for MRT-2359 plus enzalutamide in heavily pretreated mCRPC patients, presented at ASCO GU on Feb 26, 2026. Key findings: 100% PSA response (5/5) and 100% RECIST disease control in AR-mutant patients; overall RECIST DCR 67% (10/15); 10 of 15 showed tumor size reductions. Safety was manageable with mainly Grade 1–2 AEs and no discontinuations for AEs. Company plans a signal-confirming Phase 2 in AR-mutant mCRPC starting Q3 2026 to assess PSA, RECIST, rPFS and safety.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced management will present at three investor conferences in March 2026: TD Cowen (Mar 2), Barclays (Mar 10) and Jefferies Biotech on the Beach (Mar 11).
Presenters include CEO Markus Warmuth and CMO Filip Janku. Webcasts will be available via the company’s Events & Presentations page and archived for 30 days.
Monte Rosa Therapeutics (Nasdaq: GLUE) priced an underwritten public offering of 11,125,000 common shares at $24.00 per share and pre-funded warrants to purchase 1,375,000 shares at $23.9999 each. Gross proceeds are expected to be approximately $300 million, before underwriting discounts, commissions and expenses. The company granted underwriters a 30-day option to buy up to an additional 1,875,000 shares. All offered securities are being sold by Monte Rosa and the offering is expected to close on or about January 12, 2026, subject to customary closing conditions.
Jefferies, TD Cowen and Piper Sandler are joint book-running managers; Wedbush PacGrow and LifeSci Capital are passive bookrunners. The offering is made under an effective shelf registration statement declared effective March 31, 2025.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced a proposed underwritten public offering of $200.0 million of common stock and, for certain investors, pre-funded warrants to purchase common stock, with underwriters granted a 30-day option to buy up to an additional $30.0 million. The offering is subject to market and other conditions and may not be completed as proposed. The securities will be offered under an effective shelf registration declared effective by the SEC on March 31, 2025. Jefferies, TD Cowen and Piper Sandler are joint book-running managers; Wedbush PacGrow and LifeSci Capital are passive bookrunners. A preliminary prospectus supplement will be filed with the SEC.
Monte Rosa Therapeutics (NASDAQ: GLUE) announced positive interim Phase 1 data for MRT-8102, a NEK7-directed oral molecular glue degrader targeting NLRP3/IL-1/IL-6 inflammation pathways. In Part 3 (24 subjects dosed for 4 weeks as of Dec 23, 2025) median hsCRP fell 85% and 94% of subjects reached hsCRP <2 mg/L from a median baseline of 6.3 mg/L. NEK7 degradation in peripheral T cells was ~80–90% across doses (5–400 mg). Median plasma IL-6 dropped 55%; two subjects had a 75% CSF IL-6 decrease. Safety was described as favorable with mainly mild–moderate AEs and no evidence of increased infection risk. Readout of the expanded study is anticipated in H2 2026, and a Phase 2 ASCVD study is planned for 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) will present interim clinical results for the NEK7-directed molecular glue degrader MRT-8102 on Jan 7, 2026 at 8:00 a.m. ET. The presentation will highlight interim data from the ongoing Phase 1 study, including the Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk.
The event will be available via live conference call and webcast through the company’s Events & Presentations page at ir.monterosatx.com, with an archived webcast accessible for 30 days after the presentation.
Monte Rosa Therapeutics (Nasdaq: GLUE)/b) reported interim Phase 1/2 data for in heavily pretreated mCRPC patients as of Dec 3, 2025. Of 20 enrolled (14 RECIST-evaluable), the AR-mutant subgroup (4 patients) showed a 100% PSA response rate (4/4), including two PSA90s, and a 100% disease control rate with two RECIST responses. Overall RECIST-evaluable DCR was 64% (9/14). Safety was manageable, primarily Grade 1–2 gastrointestinal events. The company plans a signal-confirming Phase 2 (up to 25 patients) beginning in 2026 and will present updated data at ASCO GU in Feb 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) will present updated interim results from the Phase 1/2 study of the GSPT1-directed molecular glue degrader MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.
The company will host a live conference call and webcast on December 16, 2025 at 8:00 a.m. ET. The presentation will be available via Monte Rosa’s investor site under “Events & Presentations,” and an archived webcast will be accessible for 30 days after the event.